The binding of Norwalk virus (NV) recombinant capsids was tested in a panel of saliva samples collected from 96 donors with different ABO, secretor, and Lewis phenotypes. As previously reported, binding occurred specifically to saliva from secretors, regardless of their Lewis phenotype status. Blood group B saliva was poorly recognized, whereas binding to blood group O saliva was higher and binding to blood group A saliva was highest. Transfection of either blood group A or B enzyme into H epitope-expressing cells showed that masking of H epitopes by the A and B antigens blocked the attachment of NV capsids. The high level of binding to blood group A secretor saliva could be explained by an optimal H type 1 ligand density, which was lower than that in blood group O saliva and much higher than that in blood group B saliva. Indeed, despite a higher ligand density, saliva from homozygotes with 2 functional FUT2 alleles was less strongly recognized than saliva from heterozygotes with 1 functional and 1 inactivated FUT2 allele. Partial fucosidase treatment of duodenal tissue sections and binding to a synthetic probe with varying densities of H type 1 trisaccharide indicated that optimal attachment occurred at medium ligand density.
tein that self-assembles into virus-like particles (VLPs) when the recombinant capsid protein is expressed in baculovirus-infected insect cells [8] . The recombinant VLPs (rVLPs) are morphologically and antigenically indistinguishable from native virions and are useful in modeling virus-cell interactions.
Norwalk virus (NV) is the prototype norovirus, and we have demonstrated that NV rVLPs attach to the surface of epithelial cells in the gastroduodenal junction and to the saliva of donors with the secretor phenotype only [9] . The gene responsible for the secretor phenotype, FUT2, encodes an a1,2 fucosyltransferase that produces the carbohydrate H type 1 on the surface of the epithelial cells and in mucosal secretions, and NV rVLPs attach to this H type 1 trisaccharide (Fuca2Galb3GlcNAc). Additional glycosyltransferases, including the Lewis (FUT3) and the A and B enzymes of the ABO system, are found in epithelial cells and can modify the H type 1 structure present at the cell surface or in secretions such as saliva. Modification by addition of a second fucose residue by the FUT3 enzyme gives the Lewis b antigen (Fuca2Galb3[Fuca4]GlcNAc), and it has been reported that this difucosylated struc-ture is also recognized by NV rVLPs [10, 11] . The addition of an n-acetylgalactosamine or a galactose in an a1,3 linkage that gives the A and B antigens, respectively, could potentially mask the H type 1 epitope. A volunteer study has shown that individuals with a nonsecretor phenotype-and who, thus, are devoid of the H type 1 ligand-do not become infected with NV, indicating that its presence is required for infection [12] . Moreover, it has been reported that blood group O individuals are more susceptible to NV than are blood group A or B individuals, suggesting that the A and B antigens hinder access to the H type 1 ligand [13] . During the time since we reported our initial observation on NV, binding to carbohydrates of the histo-blood group family by recombinant capsids from other strains of noroviruses has been reported. Distinct patterns have been observed with respect to ABO, secretor, and Lewis antigenic expression for different strains [14] [15] [16] . Thus, it could be expected that distinct strains of noroviruses infect distinct subgroups of individuals, according to histo-blood group polymorphism. The capacity of recombinant capsids to attach to histo-blood group structures has been shown by analysis of red blood cell agglutination and by analysis of the binding to salivary mucins or to synthetic carbohydrates. These methods are simple and could prove to be very useful to predict which subgroup of the population is at risk for infection with any given strain, providing that recombinant capsids are available. Because the ability of native virions to infect individuals according to their ABO and secretor phenotypes has been documented for the NV strain in volunteer studies, NV rVLPs constitute a model of choice to investigate more precisely how their attachment is influenced by the combined ABO, secretor, and Lewis phenotype status and how it matches the ABO and secretor character effects on infection.
In the present study, we used saliva samples from individuals with the various ABO, secretor, and Lewis phenotypes to analyze the binding of NV rVLPs, because the expression of A, B, H, and Lewis antigens on salivary mucins matches that in the small intestine. We observed (1) that the polymorphism of the histo-blood group antigens determines NV rVLP binding to saliva but only partly matches the sensitivity to infection and (2) that the density of the H type 1 (or Le b ) ligand determines NV rVLP binding to saliva and that the optimal density for binding is intermediate.
DONORS, MATERIALS, AND METHODS
ABO, secretor, and Lewis phenotyping from saliva. Ninetysix saliva samples and swabs of buccal epithelial cells were collected. The study was approved by the Nantes University Hospital Review Board (study no. BRD02/2-P), and informed consent was obtained from all saliva donors. Saliva samples were boiled for 10 min immediately after collection and were centrifuged for 5 min at 13,000 g. Nunc immunoplates were coated with saliva samples serially diluted from 1:400 in 100 mmol/L carbonate/bicarbonate buffer (pH 9.6) by an overnight incubation at 37ЊC in a wet atmosphere. After a blocking step with PBS containing 5% defatted milk (5% milk/PBS) for 1 h at 37ЊC, primary anti-carbohydrate antibodies diluted in 5% milk/PBS were added and incubated for 2 h at 37ЊC. Alkaline phosphatase-conjugated anti-mouse immunoglobulin (Jackson laboratories) diluted in 5% milk/PBS was then added and incubated for 1 h at 37ЊC. ). Genotyping. Genomic DNA was extracted from swabs of buccal epithelial cells by use of the Qiagen QIAamp DNA Mini Kit, in accordance with the manufacturer's instructions. Genotyping for FUT2 was performed as follows. A fragment of the FUT2 gene was amplified with the primers 5 -GAGGAATA-CCGCCACATCCCGGGGGAGTAC-3 (forward) and 5 -ATG-GACCCCTACAAAGGTGCCCGGCCGGCT-3 (reverse) and was digested with Ava II. The G428A mutation abrogates this restriction site, and this mutation represents 195% of the inactivating mutations found in the French population. To discriminate between the A1 and A2 subgroups among the A secretor samples, exons 6 and 7 of the ABO gene were amplified with the primers 5 -CCGGTTGGAGTCGCATTTGCCTCTGG-TTGG-3 (exon 6; forward), 5 -CAGCAGAAGCCACCATCCC-TGGGTGAGACG-3 (exon 6; reverse), 5 -CCGAGGACTCGC-TCAGGACAGGGCAGGAG-3 (exon 7; forward), and 5 -TGG-GGACGGGGCCTAGGCTTCAGTTACTCACA-3 (exon 7; reverse), and the amplicons were sequenced. The A2 subgroup was defined by the presence of either (1) 2 alleles with the 1060 deletion on exon 7 (A2/A2) or (2) one allele with the 261 deletion on exon 6 (O allele) and the other allele with the 1060 deletion (0/A2). All other combinations were considered to be characteristic of the A1 subgroup (A1/A1, A1/A2, and A1/0). NV capsid antigen binding to saliva or synthetic carbohydrates. NV rVLPs were produced by use of a baculovirusexpression system and purified by rate-zonal centrifugation in a sucrose gradient, as described elsewhere [8] . To assay NV rVLPs binding to saliva or synthetic carbohydrates, microplates were coated with either saliva or synthetic oligosaccharides coupled to polyacrylamide as described above, and binding was detected as described elsewhere [9] . Polyacrylamide conjugates were prepared from the same activated polymer, in accordance with a previously published method [17] .
Immunohistochemical analysis. Paraffin-embedded tissue sections of the gastroduodenal junction from blood group O and A donors with the secretor phenotype were rehydrated in graded ethanol and washed in PBS. Endogenous peroxidase was inhibited by use of methanol/H 2 O 2 (0.3%) for 20 min. Tissue sections were then treated with 4 mU of fucosidase II from Xanthomonas manihotis (Glyko) in 50 mmol/L sodium phosphate buffer (pH 5.0) at 37ЊC for 6 h or for 18 h with a renewal at 6 h. A control was performed with fucosidase that had been heat inactivated by boiling in a water bath for 10 min before incubation with the tissue section. Attachment of NV rVLPs to the tissue sections was performed as described elsewhere [9] .
Flow-cytometric analysis. CHO cells are devoid of a1,2 fucosyltransferase activity and, therefore, of A, B, and H antigens. CHO cells expressing H epitopes were obtained by transfection of rat Fut2 cDNA. A or B antigenic expression was then obtained by cotransfection of these cells with either A or B enzyme cDNA, as described elsewhere [18, 19] .
For flow cytometry analysis, viable cells ( cells/well) 5 2 ϫ 10 were incubated with NV rVLPs at a concentration of 10 mg/mL in PBS containing 0.1% gelatin for 1 h at 4ЊC. After 3 washes in the same buffer, a second 45-min incubation was performed, with MAb 9C3 at a concentration of 1 mg/mL [20] . After 3 more washes in the same buffer, a third incubation was performed with fluorescein isothiocyanate (FITC)-labeled anti-mouse immunoglobulins (Sigma) under the same conditions. The presence of histo-blood group A and B antigens at the cell surface was detected by the same method but with primary antibodies 3-3A and ED3, respectively, at a concentration of 1 mg/mL and with FITC-labeled anti-mouse immunoglobulins as secondary reagents. The presence of histo-blood group H antigen was detected with FITC-labeled UEA-I lectin at a concentration of 10 mg/mL. After final washes in the same buffer, fluorescence analysis was performed on a FACScan flow cytometer with CellQuest (version 0.3.4fcb; BD Biosciences).
Statistical analysis. Comparison of the binding of NV rVLPs to saliva from various donors with the ABO, secretor, and Lewis phenotypes was performed by Student's t test. n p 12 quencies are as expected for the French population [21] .
RESULTS

Saliva phenotyping.
Dependency of NV rVLP binding to saliva on the combined ABO and secretor phenotype status. To determine the potential availability of H type 1 binding sites to saliva from donors with the various ABO, secretor, and Lewis phenotypes, we tested the capacity of an anti-H type 1 to bind to these saliva samples ( figure 1A ). As expected, the anti-H type 1 MAb did not bind to saliva from nonsecretors. Among secretors, it bound more strongly to saliva from blood group O donors than from blood group A or B donors. Saliva from blood group B donors was the less recognized. In addition, within each A, B, and O secretor subgroup, the anti-H type 1 MAb bound more strongly to Lewis-negative saliva than to Lewis-positive saliva. These results are consistent with the amount of H type 1 epitopes that one would expect to find in the various subtypes of saliva. Indeed, H type 1 epitopes should be masked by the presence of the A and B epitopes as well as by the presence of the Lewis b epitope in Lewis-positive saliva. To determine whether the ABO and Lewis phenotypes could influence the attachment and, therefore, possibly the infectivity of NV, we next tested the capacity of NV rVLPs to bind to the different subgroups of saliva. The results are shown in figure  1B . NV rVLPs bound to saliva from all secretors ( ) but n p 78 did not bind to saliva from nonsecretors ( ) ( ). n p 18 P р .001 Among secretors, binding was stronger in saliva from blood group A donors than from blood group O donors ( ) P ! .001 and was weaker in saliva from blood group B donors than from blood group O donors ( ). When the blood group A P ! .001 secretor cohort was divided into A1 and A2 subgroups, as determined by genotyping, there was no significant difference between the 2 subgroups in the binding of anti-A 3-3A, anti-H type 1 BG4, and anti-H type 2/Le y 19-OLE, indicating that the A1/A2 subgrouping is not as clear-cut when based on saliva than when based on erythrocytes. In accordance with this ob- servation, the binding of NV rVLPs was not significantly different between the A1 and A2 subgroups (data not shown). Similarly, when the A, B, or O cohorts where subdivided into Lewis-positive and Lewis-negative subgroups, there were no significant differences in NV rVLP binding, indicating that the Lewis phenotype has no effect on binding. This lack of effect is easily understandable, because NV rVLPs recognize the H type 1 and Lewis b structures equally well. However, the influence of the ABO phenotype on binding is less easily understood.
We thus tested the capacity of NV rVLPs to bind to CHO cells expressing A, B, or H epitopes. The cells expressing H epitope were obtained by transfection with rat Fut2 cDNA, and the cells expressing A and B epitopes were obtained by cotransfection of Fut2 with cDNA encoding for the rat A or B enzymes, respectively. As previously reported, it was observed, on the basis of flow cytometry, that NV rVLPs bind strongly to H epitope-expressing CHO cells and that expression of A antigen masked the H epitope and markedly decreased the binding of NV rVLPs [9] . Likewise, attachment of NV rVLPs to B epitope-expressing CHO cells was weak, indicating that both the A and B antigens can hinder the recognition of H epitopes by NV VLPs (figure 2). These results suggest that the addition of either a galactose or an n-acetylgalactosamine residue to H structures can block the binding of NV rVLPs. This clearly explains why blood type B secretor saliva is poorly recognized by NV VLPs; however, it notably fails to explain why blood type A secretor saliva is more strongly recognized than blood type O secretor saliva.
One possible explanation for this phenomenon is that optimal binding requires an optimal density of ligand. Binding is detectable at high densities, but it could increase at medium densities and disappear at low densities. If this hypothesis is true, it would resolve the contradiction noted above between the hindrance of NV rVLP binding by the presence of the A or B epitope and the high binding to blood group A secretor saliva. There would be an optimal ligand density (H type 1 or Le b ) in these samples, whereas the density would be suboptimal (too high) in blood group O secretor saliva and too low in blood group B secretor saliva.
Dependency of NV rVLP binding on ligand density. During the course of our earlier studies of the binding of NV rVLPs to human tissue sections, we observed that VLP binding was dependent on the presence of a fucose in an a1,2 linkage, given that removal of this residue by a specific a1,2 fucosidase resulted in the loss of NV VLP binding [9] . However, this result was obtained after an 18-h fucosidase treatment with renewal of the enzyme after 6 h. A simple 6-h treatment resulted in an increase, rather than a decrease, in NV rVLP binding ( figure  3 ). To further test our hypothesis, we used synthetic H trisaccharides conjugated to polyacrylamide at various densities. As is shown in figure 4 , the binding of NV rVLPs to H type 1 was strongest at a 20% carbohydrate:polyacrylamide ratio and was weakest at both higher and lower ratios. Almost no binding to H type 2 was detected, irrespective of the carbohydrate:polyacrylamide ratio.
To confirm that the binding of NV rVLPs depends on an optimal density of H epitopes, we tested their capacity to bind to saliva from secretor donors who were either homozygous or heterozygous at the FUT2 locus. Homozygotes who have 2 functional alleles are expected to synthesize more H epitopes than heterozygotes who have only 1 functional allele. In the European population, a single inactivating mutation of the FUT2 gene, G428A, accounts for the nonsecretor character [22] . In the present study, a search for this mutation among the 96 donors revealed that the 18 nonsecretors were homozygous for the mutated allele. Among secretors, 57 were heterozygous and 21 were homozygous for the wild-type functional allele. Because the presence of the A or B antigen influences the availability of H type 1 epitopes, we looked at the effect of FUT2 status on NV rVLPs binding among blood group O secretors only. In this subgroup, 11 were heterozygous and 9 were homozygous at the FUT2 locus. As expected, the binding of an anti-H type 1 MAb was stronger in saliva from homozygous secretors than in saliva from heterozygous secretors ( , at a saliva dilution of 1:400) (figure P ! .05 5A). Inversely, NV rVLPs bound more strongly to saliva from heterozygotes than from homozygotes; 50% maximum binding was obtained at a 2-fold higher dilution for homozygotes than for heterozygotes ( , at saliva dilutions of 1:102,400 and P ! .05 1:204,800), confirming that the higher epitope density is not optimal for the binding of NV rVLPs (figure 5B).
DISCUSSION
NV rVLPs bind to the a1,2 fucose-containing H type 1, H type 3, and Le b oligosaccharides [9] [10] [11] . Meanwhile, the availabil- ity of the H and Le b epitopes can be modulated by interaction with the products of the ABO alleles. Thus, the addition of an n-acetylgalactosamine or a galactose by the histo-blood group A or B enzyme, respectively, can potentially mask these epitopes, lowering the risk of infection for blood group A or B individuals; indeed, 2 independent volunteer studies have shown that blood group A and B individuals are at lower risk for being infected than are blood group O individuals [12, 13] . Additionally, it is expected that, among secretors, FUT2 heterozygotes should synthesize lower amounts of a1,2 fucosylated glycans than should homozygotes. This may affect the risk of infection as well. In the present study, we tried to define how ABO and FUT2 phenotype status affects NV rVLPs binding, to relate our results to those obtained in vivo through volunteers studies. We chose to study the binding of NV rVLPs to saliva, because it is readily available and because the presence of the various histo-blood group antigens in this fluid matches that of gut surface epithelial cells.
The present results confirmed our original findings in that NV rVLPs did not bind to any saliva sample from nonsecretors. Among secretors, the Lewis phenotype status has no influence. It is expected, therefore, that the polymorphism at the FUT3 level should not influence infection. Because of the low frequency of the Lewis-negative (FUT3 Ϫ/Ϫ ) secretor phenotype, this has not been tested in volunteer studies to date. The patterns of NV rVLP binding to saliva from individuals with distinct ABO phenotypes have been reported in 2 earlier studies. Both studies failed to reveal binding to blood type B secretor saliva [11, 14] . This somewhat contradicts the fact that some blood type B volunteers can be infected in challenge studies [12, 13] . Our results show that NV rVLPs do bind to blood type B secretor saliva, albeit at a level lower than that for blood type O or A secretor saliva. This finding is in agreement with the observation that blood type B individuals have a decreased risk of infection and symptomatic disease, compared with blood type A or O individuals. The difference between the present saliva-binding study and the earlier ones is that we tested NV rVLP attachment over a wide range of saliva dilutions (from 1:400 to 1:512,000). The results presented correspond to the lowest dilution. At higher dilutions, binding to blood type B saliva becomes difficult to detect in most cases, whereas binding to either blood type A or O secretor saliva is still detectable. In the earlier studies, a single saliva dilution was tested, one that likely was too high to detect any binding of NV rVLPs to blood type B saliva. Hutson et al. reported that NV rVLPs could agglutinate human red blood cells at 4ЊC and that this agglutination was dependent on the presence of H epitopes [10] . Similar to our results for saliva binding, agglutination was modulated by the ABO phenotype of the donor, with blood group B erythrocytes often not agglutinated and blood group A erythrocytes more strongly agglutinated than blood group O erythrocytes.
The radiograph crystallographic structure of NV rVLPs indicates that they are composed of 90 dimers of the single capsid protein, which folds into 3 domains to form a shell and protruding arches [23] . They can, therefore, present multiple binding sites for a1,2 fucosylated structures on a rigid shell, suggesting that a specific arrangement or density of the carbohydrate ligand allows optimal attachment to a cell surface or to coated salivary mucins. Our results indicate that NV rVLP binding is indeed ligand-density dependant. One may, therefore, expect that, among secretors, the risk of infection will vary in a complex manner depending on the optimal density of the H type 1 or Le b ligand available that corresponds to a medium density. Thus, the strong NV rVLP binding to blood group A secretor saliva could be accounted for by an optimal density of available ligands. However, this is at odds with the observation that blood group O individuals, but not blood group A individuals, have the highest infection rate, indicating that the pattern of binding of NV VLPs to salivary mucins only partially matches the pattern of infection.
More studies are required to understand the discrepancy between the strong capacity of NV rVLPs to bind to histo-blood group A salivary mucins and the low infection rate of blood group A individuals and to define the genetic components of susceptibility and resistance to other strains of norovirus.
